SecBot SecBot
8-K ·Filed Sep 1, 2026

INDP

Indaptus Therapeutics, Inc.
BEARISH
Impact 5/10
Horizonweeks Processed2mo ago SEC0001493152-26-040926
8-K Item 1.01 + 5.02 (likely routine officer/director compensation agreement)
Actionable Insight ▼ Bearish

Monitor the company's daily trading volume and any subsequent 8-K or prospectus supplement filings for actual share sales under the ATM program. The large authorized amount ($100M vs $153M market cap) creates persistent overhang; any material volume of sales would likely pressure the stock price.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$1.13
T+0 close · Sep 1, 2026 · via day close
Latest settled
+104.87%
T+20 · $2.32 · next T+60 in 8d
Vs SPY
+103.69%
α at T+20
Latest observation
+390.10%
T+52 · FF3 residual α
  1. T+0 · Sep 1 $1.13entry
  2. T+1 · 3mo ago +3.54%α +3.10% · $1.17
  3. T+5 · 2mo ago +84.07%α +83.99% · $2.08
  4. T+20 · 7w ago +104.87%α +103.69% · $2.32
  5. T+53 · todayOpen
  6. T+60 · in 8d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Indaptus Therapeutics entered into an amended and restated at-the-market offering agreement with H.C. Wainwright, enabling the sale of up to $100 million in common stock. This filing, combined with the prospectus supplement filed the prior day, formalizes a significant capital raise capacity for the clinical-stage biotech. The potential for substantial dilution overhangs the stock, though the company has no obligation to sell any shares.

Key Facts

  • Indaptus entered into an Amended and Restated At the Market Offering Agreement with H.C. Wainwright for up to $100,000,000 in common stock.
  • The agreement amends and restates the prior June 1, 2022 agreement.
  • H.C. Wainwright will receive a 3.0% placement fee on shares sold as agent.
  • The company filed a related prospectus supplement on August 31, 2026.
  • As of August 26, 2026, the last reported sale price was $1.14 per share.
  • Prior sales under the original agreement totaled approximately $2.74 million (520,000 shares at ~$2.34M and 5,428 shares at ~$0.4M).

Financial Impact

Up to $100,000,000 in potential common stock sales, creating significant dilution risk for existing shareholders.

dilutionshare count

Risk Factors

  • Significant dilution if the full $100 million ATM is utilized.
  • Stock price pressure from continuous selling into the market.
  • Clinical-stage biotech with no approved products, making equity financing a primary capital source.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-040926
Exhibit: ex5-1.htm0001493152-26-040926
Document: form8-k.htm0001493152-26-040926
Document: 0001493152-26-040926-index-headers.html0001493152-26-040926
Document: 0001493152-26-040926-index.html0001493152-26-040926
Document: 0001493152-26-040926.txt0001493152-26-040926

Track record

20 reports on INDP

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +59.35% at T+20 after the Jul 20, 2026 report. 6 of 9 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $3.17 Now $3.45 +8.83% settles Dec 15
  2. Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  3. Oct 22, 202625d ago SC 13D/A Neutral 3/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  4. Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  5. Oct 21, 202626d ago SC 13D/A Neutral 4/10 Entry $2.99 Now $3.45 +15.38% settles Nov 19
  6. Oct 20, 202627d ago 8-K Bearish 6/10 Entry $3.16 Now $3.45 −9.18% settles Nov 18
  7. Sep 30, 20266w ago 8-K Neutral 3/10 Entry $2.30 to $3.31 Now $3.45 +50.00% ▲ +43.70% +42.43% vs SPY
  8. Sep 9, 20269w ago 8-K Bearish 7/10 Entry $2.56 to $2.37 Now $3.45 −34.77% ▲ +7.42% +9.55% vs SPY
  9. Sep 4, 202610w ago 424B5 Bearish 6/10 Entry $1.85 to $2.59 Now $3.45 −86.49% ▼ −40.00% −38.29% vs SPY
  10. Sep 1, 202610w ago 8-K Bearish 5/10 Viewing Entry $1.13 to $2.32 Now $3.45 −205.31% ▼ −104.87% −103.69% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 1, 2026